Aspire Biopharma Holdings Inc. has announced positive top-line results from a recent clinical trial of their investigational sublingual aspirin product for the treatment of suspected acute myocardial infarction. The trial demonstrated that Aspire's sublingual aspirin provides a higher and more rapid therapeutic impact compared to standard chewed aspirin tablets. The product was found to be safe and well-tolerated in the study. Aspire plans to review these results with the FDA to potentially pursue accelerated approval. The clinical trial, AB-101, was a randomized crossover bioavailability study involving healthy adults, assessing the safety, tolerability, pharmacokinetics, and pharmacodynamics of the sublingual aspirin.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1061839) on August 18, 2025, and is solely responsible for the information contained therein.